Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review. Issue 12 (22nd December 2021)

• Record Type: Journal Article
• Authors: Tomomasa, Dan; Isoda, Takeshi; Mitsuiki, Noriko; Yamashita, Motoi; Morishita, Aoi; Tomoda, Takahiro; Okano, Tsubasa; Endo, Akifumi; Kamiya, Takahiro; Yanagimachi, Masakatsu; Imai, Kohsuke; Kanegane, Hirokazu; Takagi, Masatoshi; Morio, Tomohiro
• Is Part Of: Clinical case reports. Volume 9:Issue 12(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12-22
• Subjects: graft‐versus‐host disease -- hemophagocytic lymphohistiocytosis -- idiopathic pneumonia syndrome -- myelodysplastic syndrome -- ruxolitinib; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5242
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT‐related IPS. Abstract : Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib may be an alternative choice for HSCT‐related IPS.